This Healthcare Stock Jumps Around 188%, Here’s 83 Biggest Movers From Yesterday
Gainers
Evofem Biosciences, Inc. (NASDAQ: EVFM) shares jumped 187.7% to close at $1.07 on Monday amid the Supreme Court overturning Roe V Wade.
Why Is NeuroSense Therapeutics Surging by 70%? 46 Stocks Moving In Monday’s Mid-Day Session
Gainers
Evofem Biosciences, Inc. (NASDAQ: EVFM) rose 87.3% to $0.6965 amid the Supreme Court overturning Roe V Wade.
The Daily Biotech Pulse: CHMP Backs AstraZeneca’s Breast Cancer Therapies, Ipsen Buys Epizyme, FDA Holds For Nuvation Bio, Astellas Studies
Here's a roundup of top developments in the biotech space over the last 24 hours:
Axsome Therapeutics Rallies 40% On FDA Product Label Proposal, But Analyst Remains Skeptical
Axsome Therapeutics Inc (NASDAQ: AXSM) shares rallied 40% on Monday morning after the company received some positive news from the U.S. Food and Drug Administration regarding its AXS-05 novel treatment for MDD (depression).
Why Axsome Therapeutics Stock Is Soaring Today
Axsome Therapeutics Inc (NASDAQ: AXSM) shares are trading higher Monday after the company received proposed labeling from the U.S. Food and Drug Administration for its treatment of major depressive disorder.
Where Axsome Therapeutics Stands With Analysts
Analysts have provided the following ratings for Axsome Therapeutics (NASDAQ:AXSM) within the last quarter:
Mizuho Maintains Buy on Axsome Therapeutics, Lowers Price Target to $49
Mizuho analyst Vamil Divan maintains Axsome Therapeutics (NASDAQ:AXSM) with a Buy and lowers the price target from $51 to $49.
FDA Issues Complete Response Letter (CRL) to Axsome Therapeutics for AXS-07 In Acute Migraine
The U.S. Food and Drug Administration (FDA) issued a Complete Response Letter (CRL) to Axsome Therapeutics, Inc. (NASDAQ: AXSM) regarding its New Drug Application (NDA) for AXS-07 for the acute treatment of migraine.
5 Trending Tickers On Benzinga For May 2, 2022: Activision, SoundHound And More
Benzinga’s “Daily Brief On Trending Tickers” highlights top-searched tickers from around the web and uses the Benzinga Pro platform to highlight recent news items possibly impacting those stocks.
As Expected, FDA Rejects Axsome Therapeutics’ Migraine Candidate
The FDA has issued a Complete Response Letter (CRL) to Axsome Therapeutics Inc’s (NASDAQ:AXSM) AXS-07 for the acute treatment of migraine. The…